sodium (3R,5S,6E)-7-[2-(2H5)cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate

• ChemBase编号: 176805
• 分子式: C25H23FNNaO4
• 平均质量: 443.4425932
• 单一同位素质量: 443.15088072
• SMILES: c12c(c(c(c(n1)C1CC1)/C=C/[C@H](C[C@H](CC(=O)[O-])O)O)c1ccc(cc1)F)cccc2.[Na+]
• Canonical SMILES: O[C@H](C[C@@H](/C=C/c1c(nc2c(c1c1ccc(cc1)F)cccc2)C1CC1)O)CC(=O)[O-].[Na+]
• InChI: InChI=1S/C25H24FNO4.Na/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31;/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31);/q;+1/p-1/b12-11+;/t18-,19-;/m1./s1
• InChIKey: NBDQGOCGYHMDSJ-NRFPMOEYSA-M

名称和登记号

名称

• IUPAC标准名: sodium (3R,5S,6E)-7-[2-(^2H₅)cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
• IUPAC传统名: sodium (3R,5S,6E)-7-[2-(^2H₅)cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
• 别名: (3R,5S,6E)-7-[2-(Cyclopropyl-d5)-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic Acid Sodium Salt; (+)-(3R,5S,6E)-7-[2-(Cyclopropyl-d5)-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic Acid Sodium Salt; NK 104-d5 Sodium Salt; Pitavastatin-d5 Sodium Salt

登记号

• PubChem SID: 164232715
• PubChem CID: 71751706

理论计算性质

• Log P: 2.9240363
• 摩尔折射率: 126.5763 cm^3
• 极化性: 46.6947 Å^3
• 极化表面积: 93.48 Å^2
• 可自由旋转的化学键: 8
• 里宾斯基五规则: true
• Acid pKa: 4.1270967
• 质子受体: 5
• 质子供体: 2
• LogD (pH = 5.5): 2.5521677
• LogD (pH = 7.4): 0.88797456

分子性质

理化性质

• 溶解度: Methanol
• 外观: Off-White Solid
• 熔点: 210-214°C (dec.)

安全信息

• 保存条件: Hygroscopic, -20°C Freezer, Under Inert Atmosphere

详细说明

Toronto Research Chemicals - P531007

Labelled Pitavastatin. A HMG CoA reductase inhibitor. An antilipemic.

参考文献

• Yen, H., et al.: J. Clin. Invest., 98, 1253 (1996)
• Zou, Y., et al.: J. Biol. Chem., 274, 9760 (1996)
• Sun, X., et al.: Cancer Res., et al.: 61, 3382 (1996)
• Ladas, E.J., et al.: Clin. Oncol., 22, 517 (1996)